Reversible Cerebral Vasoconstriction Syndrome Triggered by Whole-Body Cryotherapy in a Teenager.

J Child NeurolDec 26, 2025 (epub)

Marina Dantas, Kasparas Zilinskas, Christina Shen et al.

✦ AI-curated · Sources linked

Case in brief

An adolescent developed symptoms of reversible cerebral vasoconstriction syndrome (RCVS) after a whole-body cryotherapy session. The case report describes the diagnosis in the setting of this preceding exposure. The abstract does not specify the presenting symptoms, diagnostic findings, treatment, or clinical outcome, so these details cannot be summarized. RCVS is uncommon in children and can be complicated by intracranial bleeding or ischemic stroke, despite usually favorable outcomes.

What made this case unusual

Whole-body cryotherapy preceded RCVS in an adolescent, although it is not an officially recognized trigger and evidence linking it to RCVS is limited to none.

Diagnostic / clinical pearl

Consider RCVS in children with a compatible presentation, and ask about recent exposures that may be potential triggers; this report raises whole-body cryotherapy as one such possible exposure, not an established cause.

Why it matters

The case draws attention to a possible adverse effect of whole-body cryotherapy, for which the authors note limited evidence on benefits and well-studied side effects.

Source

Published in J Child Neurol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.